From the impact of Obamacare to cutting-edge research, biotech buyouts to Big Pharma court battles, The Motley Fool's health-care team sits down each week to discuss the most fascinating developments in health care, and their implications for long-term investors. In this week's edition, the team talks about Novartis' patent dispute, stocks that have both popped and plummeted, and companies our analysts will be watching in the coming days.

In the following segment, health-care analyst David Williamson chooses Alkermes as his stock to watch this week. Watch and find out why this extended-release-technology company could bring extended returns to investors.

Brenton Flynn, Max Macaluso, Ph.D.David Williamson, and The Motley Fool have no position in any stocks mentioned. Follow David on Twitter: @MotleyDavid.

Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.